Dogwood Therapeutics
- Company typePublic
- Founded2012
- HeadquartersAlpharetta, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Dogwood Therapeutics firmographics
Firmographics- Name
- Dogwood Therapeutics
- Legal name
- Dogwood Therapeutics, Inc.
- Website
- https://dwtx.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Dogwood Therapeutics industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)
Keywords
Where Dogwood Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Alpharetta
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Dogwood Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Pre-revenue development-stage company. Once FDA-approved, plans to generate revenue through sales of prescription pharmaceuticals (Halneuron and SP16) distributed through pharmacy channels to cancer patients and healthcare providers.
- Licensing Royalties and Milestone Payments: Partnership with PRIDCor Therapeutics for anti-viral candidates IMC-1 and IMC-2 entitles Dogwood to tiered royalties up to 15% on net sales, 9% of future capital raised by PRIDCor, and development/regulatory milestone payments with total potential value capped at $100 million.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Dogwood Therapeutics product offering
Product offeringCore offering
Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, non-opioid therapeutics for chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced peripheral neuropathy (CIPN). Its lead candidate Halneuron is a NaV 1.7 sodium channel blocker in Phase 2b with FDA Fast Track designation, and SP16 IV is an LRP1 agonist peptide entering Phase 1b development under a royalty-free global license from Serpin Pharma.
Product overview
Dogwood Therapeutics is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The proprietary pipeline includes two first-in-class development candidates: Halneuron, a NaV 1.7 sodium channel inhibitor in Phase 2b development for chemotherapy-induced neuropathic pain with FDA fast track designation, and SP16 IV, an LRP1 agonist peptide in Phase 1b development for chemotherapy-induced peripheral neuropathy. The company previously held antiviral assets IMC-1 (fibromyalgia) and IMC-2 (Long-COVID), which were licensed to PRIDCor Therapeutics in April 2026 for potential payments up to $100 million, allowing Dogwood to shift focus to its pain treatment pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Halneuron
Quantifiable outcome
- 4.3-4.5% dropout rate vs 20%+ for duloxetine and 30-40% for pregabalin in chronic pain medications
- +2 more outcomes
Companies that use Dogwood Therapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
Dogwood Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dogwood Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- PRIDCor TherapeuticsmajorGlobal development and commercialization partnership for anti-viral candidates IMC-1 and IMC-2. PRIDCor receives full responsibility for development, commercialization, and IP maintenance. Dogwood entitled to tiered royalties up to 15% on net sales, 9% of future capital raised, and development/regulatory milestone payments. Potential total payments capped at $100 million.
- National Cancer Institute (NCI)core$2.5 million National Cancer Institute grant fully funding Phase 1b clinical trial of SP16 at University of Virginia Cancer Center
- University of VirginiacorePhase 1b clinical trial for SP16 to be conducted at University of Virginia Cancer Center under leadership of Dr. Patrick Dillon, with patient enrollment expected mid-2026
- Serpin PharmacoreExclusive royalty-free global license to develop Serpin Pharma's intravenous formulation of SP16 for chemotherapy-induced peripheral neuropathy. Dogwood issued Series A-2 preferred stock as consideration. Phase 1b trial fully funded by $2.5M NCI grant.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Dogwood Therapeutics competitors and assessment
Company assessmentDirect peers
- Lexicon Pharmaceuticals: Clinical-stage biotech developing LX9211 (a non-opioid analgesic) for chemotherapy-induced neuropathic pain, directly competing with Dogwood's Halneuron in the same CINP indication with similar mechanism differentiation.
- Tonix Pharmaceuticals: Specialty CNS biopharma developing TNX-102 SL for fibromyalgia and other CNS/pain indications; comparable clinical-stage pain pipeline targeting similar unmet needs as Dogwood's legacy IMC-1 program.
- Cara Therapeutics: Late-stage specialty pharma developing difelikefalin (Korsuva), an opioid-sparing therapy for pruritus and pain in chronic conditions; comparable clinical/commercial pain specialty focus and stage.
- Heron Therapeutics: Specialty oncology-supportive-care pharma with approved CINV products; comparable focus on improving chemotherapy patient outcomes (CINV/pain) and similar distribution channel strategy into oncology centers.
- Trevena Inc. Clinical-stage pain biopharma developing novel CNS-targeted analgesics, including OLINVYK (already approved IV opioid); comparable clinical-stage pain pipeline targeting non-opioid or specialty positioning.
Broad incumbents
- Vertex Pharmaceuticals: Large biopharma that developed and commercialized VX-548, a non-opioid NaV 1.8 inhibitor for acute pain; relevant historical comparator in the NaV channel pain space where Dogwood's Halneuron also operates.
- Collegium Pharmaceutical: Established specialty pain pharma with a portfolio including abuse-deterrent opioids; comparable pain specialty commercialization model that Dogwood plans to adopt post-approval.
- Pfizer: Large pharma that has historically pursued CIPN/CINP programs (e.g., tanezumab); relevant comparator as a potential acquirer or competitive threat given scope and resources in neuropathic pain.
Emerging players
- Algo Therapeutics: Emerging clinical-stage developer of non-opioid pain therapies with mechanism overlap to Halneuron's NaV 1.7 focus; potential competing pipeline entrant in the same indication space.
- Hyloris Pharmaceuticals: Specialty pharma focused on reformulated and repurposed pain/CNS therapeutics; comparable development-stage profile and specialty commercialization model targeting unmet pain indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Dogwood Therapeutics social profiles
Digital presenceDogwood Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dogwood Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Dogwood Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries5 records
Dogwood Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dogwood Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dogwood Therapeutics
What does Dogwood Therapeutics do?
Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, non-opioid therapeutics for chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced peripheral neuropathy (CIPN). Its lead candidate Halneuron is a NaV 1.7 sodium channel blocker in Phase 2b with FDA Fast Track designation, and SP16 IV is an LRP1 agonist peptide entering Phase 1b development under a royalty-free global license from Serpin Pharma.
Is Dogwood Therapeutics a public or private company?
Dogwood Therapeutics is a public company. It is classified as public and is currently operating.
When was Dogwood Therapeutics founded?
Dogwood Therapeutics was founded in 2012. It employs 1 to 10 people.
Where is Dogwood Therapeutics based?
Dogwood Therapeutics is headquartered in Alpharetta, United States, in the North America region.
How does Dogwood Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties and Milestone Payments.
Who are Dogwood Therapeutics's main competitors?
Direct peers on record are Lexicon Pharmaceuticals, Tonix Pharmaceuticals, Cara Therapeutics, Heron Therapeutics and Trevena Inc.. Broad incumbents are Vertex Pharmaceuticals, Collegium Pharmaceutical and Pfizer. Emerging players are Algo Therapeutics and Hyloris Pharmaceuticals.
Does Dogwood Therapeutics have an API?
No public API is recorded for Dogwood Therapeutics.
What industry is Dogwood Therapeutics in?
Dogwood Therapeutics's product category is Clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAMAEAF, Pain Management, Anesthesia & Critical Care Drugs. Its NAICS code is 541714 and its SIC code is 2834.